Cargando…

A NOVEL B7H3/NKP30 BISPECIFIC NK CELL ENGAGER FOR CANCER IMMUNOTHERAPY

BACKGROUND AND SIGNIFICANCE: Biological therapies harnessing the adaptive immune system have achieved a great success, given the clinical efficacy of CAR-T therapies and CD3 based T cell engagers in treating hematologic tumors, and the application of T cell immune checkpoint inhibitors in various in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Xiaoling, Wu, Chongbing, Chen, Zi, Yin, Liusong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370434/ http://dx.doi.org/10.1093/abt/tbad014.013

Ejemplares similares

Influenza A Virus Hemagglutinin and Other Pathogen Glycoprotein Interactions with NK Cell Natural Cytotoxicity Receptors NKp46, NKp44, and NKp30
por: Luczo, Jasmina M., et al.
Publicado: (2021)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
por: Peipp, Matthias, et al.
Publicado: (2015)

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
por: Trabanelli, Sara, et al.
Publicado: (2017)

Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles
por: Ponath, Viviane, et al.
Publicado: (2021)

Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions
por: Garcia-Iglesias, Trinidad, et al.
Publicado: (2009)

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
por: Han, Bin, et al.
Publicado: (2018)

Expression Analysis of the Ligands for the Natural Killer Cell Receptors NKp30 and NKp44
por: Byrd, Andreina, et al.
Publicado: (2007)

Activatory Receptor NKp30 Predicts NK Cell Activation During Controlled Human Malaria Infection
por: Walk, Jona, et al.
Publicado: (2019)

NKp30(+) NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B
por: Shen, Xiaokun, et al.
Publicado: (2016)

Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
por: Ferlazzo, Guido, et al.
Publicado: (2002)

Modulation of NKp30- and NKp46-Mediated Natural Killer Cell Responses by Poxviral Hemagglutinin
por: Jarahian, Mostafa, et al.
Publicado: (2011)

Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1
por: Walwyn-Brown, Katherine, et al.
Publicado: (2018)

NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint
por: Shemesh, Avishai, et al.
Publicado: (2016)

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
por: Brandt, Cameron S., et al.
Publicado: (2009)

Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection
por: Yang, Huabing, et al.
Publicado: (2023)

Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6
por: Li, Yili, et al.
Publicado: (2011)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
por: Nikkhoi, Shahryar Khoshtinat, et al.
Publicado: (2023)

NKp46‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats
por: Lipinski, Britta, et al.
Publicado: (2023)

Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
por: Arulanandam, Antonio, et al.
Publicado: (2023)

NKp46 Clusters at the Immune Synapse and Regulates NK Cell Polarization
por: Hadad, Uzi, et al.
Publicado: (2015)

Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex
por: Chen, Jihong, et al.
Publicado: (2022)

Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy
por: Zamai, Loris, et al.
Publicado: (2020)

NKp46 defines ovine cells that have characteristics corresponding to NK cells
por: Connelley, Timothy, et al.
Publicado: (2011)

NK Cell Receptor NKp46 Regulates Graft-versus-Host Disease
por: Ghadially, Hormas, et al.
Publicado: (2014)

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
por: Gauthier, Laurent, et al.
Publicado: (2023)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression
por: Glasner, Ariella, et al.
Publicado: (2017)

Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma
por: Iraqi, Muhammed, et al.
Publicado: (2022)

Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk
por: Chinnery, Fay, et al.
Publicado: (2012)

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
por: Wu, Jingjing, et al.
Publicado: (2015)

P842: NOVEL MULTIFUNCTIONAL TETRAVALENT CD38 NKP46 FLEX-NK ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE MYELOMA CELLS
por: Lin, L., et al.
Publicado: (2022)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Differential Expression of LLT1, SLAM Receptors CS1 and 2B4 and NCR Receptors NKp46 and NKp30 in Pediatric Acute Lymphoblastic Leukemia (ALL)
por: Powers, Sheila B., et al.
Publicado: (2023)

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2018)

NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure
por: Zou, Yong, et al.
Publicado: (2015)

Evaluation of NKp46 expression and cytokine production of decidual NK cells in women with recurrent pregnancy loss
por: Yamamoto, Mayu, et al.
Publicado: (2022)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
por: Xiao, Xinghui, et al.
Publicado: (2023)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
por: Carrara, Stefania C., et al.
Publicado: (2022)

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
por: Floerchinger, Alessia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rnmu1qfoh563t0j3030at3cdb1